The German Federal Joint Committee's (G-BA) decision of April 16, 2026, to classify the additional benefit of Donanemab as „not substantiated“ does not surprise the digiDEM project management. The G-BA had already reached this conclusion for Lecanemab in February 2026 of this year. Now it appears that the second drug with a similar mechanism of action also cannot...
In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
In the third issue of our new special newsletter "SCHLAGLICHT – New Medications for Dementia," Dr. Nikolas Dietzel, a research associate at digiDEM Bayern, discusses the publication by scientists from Europe, the USA, and Australia, led by Professor Poul F. Høilund-Carlsen from Odense University Hospital in Denmark. In the article titled "Donanemab, another anti-Alzheimer’s…"
In the second part of our new special newsletter, SCHLAGLICHT – New Dementia Medications, Jana Rühl, a research associate at digiDEM Bavaria, discusses the publication by the research team led by Professor Sören Mattke from the University of Southern California. Today, we address the question of whether healthcare systems can even cope with the diagnostic requirements...
SPOTLIGHT – New Medications for Dementia – this is the name of our new series on new active ingredients for the treatment of Alzheimer's disease. We want to shed „spotlight“ on the multifaceted topic of „New Dementia Medications and Challenges for Everyday Care.“ These new medications are intended for people in the early stages of the disease or in the mild phase...
